.: ORİJİNAL ARAŞTIRMA
Results of 100 Units of Botulinum Toxin Administration in Overactive Bladder Treatment
Aşırı Aktif Mesane Tedavisinde 100 Ünite Botulinum Toksini Uygulamasının Sonuçları
J Reconstr Urol. 2021;11(1):29-35
doi: 10.5336/urology.2021-81573
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: This study aimed to analyze the efficiency and safety of botulinum toxin in patients who presented to urology clinic with overactive bladder (OAB). Material and Methods: Between 2015 and 2019, forty patients who were administered intravesical 100 units of botulinum toxin for OAB treatment were evaluated retrospectively in terms of efficacy and safety. Efficacy was evaluated by using the treatment benefit scale (TBS) at 3 months after injection The quality of life for OAB symptoms was evaluated via the incontinence quality of life scale before treatment and at the 3rd month after treatment. Likewise, parameters such as incontinence, nocturia, urinary frequency, post-void residual urine values, maximum urine flow rate, number of pads used were evaluated before and at the 3rd month after the procedure. Results: Significant increases were detected in post-procedure incontinence quality of life scores compared to pre-procedure, and in parallel with these results, significant increases were recorded in the post-treatment questionnaire (38.5±15.0 and 69.9±6.3, respectively); p<0.001). In addition, according to the TBS results at the 3rd month, 80% of the patients who underwent the procedure did benefit from the treatment. Conclusion: Botulinum toxin injection still remains to be an effective option in refractory OAB treatment.
Keywords: Urinary incontinence; botulinum toxin; treatment outcome
Objective: This study aimed to analyze the efficiency and safety of botulinum toxin in patients who presented to urology clinic with overactive bladder (OAB). Material and Methods: Between 2015 and 2019, forty patients who were administered intravesical 100 units of botulinum toxin for OAB treatment were evaluated retrospectively in terms of efficacy and safety. Efficacy was evaluated by using the treatment benefit scale (TBS) at 3 months after injection The quality of life for OAB symptoms was evaluated via the incontinence quality of life scale before treatment and at the 3rd month after treatment. Likewise, parameters such as incontinence, nocturia, urinary frequency, post-void residual urine values, maximum urine flow rate, number of pads used were evaluated before and at the 3rd month after the procedure. Results: Significant increases were detected in post-procedure incontinence quality of life scores compared to pre-procedure, and in parallel with these results, significant increases were recorded in the post-treatment questionnaire (38.5±15.0 and 69.9±6.3, respectively); p<0.001). In addition, according to the TBS results at the 3rd month, 80% of the patients who underwent the procedure did benefit from the treatment. Conclusion: Botulinum toxin injection still remains to be an effective option in refractory OAB treatment.
Keywords: Urinary incontinence; botulinum toxin; treatment outcome
ÖZET
Amaç: Bu çalışma, aşırı aktif mesane (AAM) ile üroloji kliniğine başvuran hastalarda botulinum toksininin etkinliğini ve güvenliğini incelemeyi amaçlanmıştır. Gereç ve Yöntemler: 2015- 2019 yılları arasında AAM tedavisi için intravezikal 100 ünite botulinum toksini uygulanan 40 hasta, etkinlik ve güvenlik açısından retrospektif olarak değerlendirildi. Etkinlik, enjeksiyondan 3 ay sonra tedavi fayda ölçeği kullanılarak değerlendirildi. AAM semptomlarının yaşam kalitesine etkisi, tedavi öncesinde ve tedavi sonrası 3. Ayda inkontinans yaşam kalitesi ölçeğiyle değerlendirildi. Aynı şekilde işlem öncesinde ve işlem sonrası 3. ayda inkontinans, noktüri, idrar sıklığı, post-miksiyonel rezidü değerleri, maksimum idrar akım hızı, kullanılan ped sayısı gibi parametreler değerlendirildi. Bulgular: İşlem sonrası inkontinans yaşam kalitesi skorlarında işlem öncesine göre anlamlı bir artış gözlendi ve bu sonuçlarla uyumlu olarak tedavi sonrası ankette anlamlı artış saptandı (sırasıyla 38,5±15,0 ve 69,9±6,3); p<0,001). Ayrıca 3. aydaki sonuçlarına göre işlem uygulanan hastaların %80'i tedaviden fayda gördü. Sonuç: Botulinum toksin enjeksiyonu, dirençli AAM tedavisinde etkili bir seçenek olmaya devam etmektedir.
Anahtar Kelimeler: Üriner inkontinans; botulinum toksini; tedavi sonucu
Amaç: Bu çalışma, aşırı aktif mesane (AAM) ile üroloji kliniğine başvuran hastalarda botulinum toksininin etkinliğini ve güvenliğini incelemeyi amaçlanmıştır. Gereç ve Yöntemler: 2015- 2019 yılları arasında AAM tedavisi için intravezikal 100 ünite botulinum toksini uygulanan 40 hasta, etkinlik ve güvenlik açısından retrospektif olarak değerlendirildi. Etkinlik, enjeksiyondan 3 ay sonra tedavi fayda ölçeği kullanılarak değerlendirildi. AAM semptomlarının yaşam kalitesine etkisi, tedavi öncesinde ve tedavi sonrası 3. Ayda inkontinans yaşam kalitesi ölçeğiyle değerlendirildi. Aynı şekilde işlem öncesinde ve işlem sonrası 3. ayda inkontinans, noktüri, idrar sıklığı, post-miksiyonel rezidü değerleri, maksimum idrar akım hızı, kullanılan ped sayısı gibi parametreler değerlendirildi. Bulgular: İşlem sonrası inkontinans yaşam kalitesi skorlarında işlem öncesine göre anlamlı bir artış gözlendi ve bu sonuçlarla uyumlu olarak tedavi sonrası ankette anlamlı artış saptandı (sırasıyla 38,5±15,0 ve 69,9±6,3); p<0,001). Ayrıca 3. aydaki sonuçlarına göre işlem uygulanan hastaların %80'i tedaviden fayda gördü. Sonuç: Botulinum toksin enjeksiyonu, dirençli AAM tedavisinde etkili bir seçenek olmaya devam etmektedir.
Anahtar Kelimeler: Üriner inkontinans; botulinum toksini; tedavi sonucu
REFERANSLAR:
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. [Crossref] [PubMed]
- Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-6. Erratum in: BJU Int. 2001;88(7):807. [Crossref] [PubMed]
- Asimakopoulos AD, Cerruto MA, Del Popolo G, La Martina M, Artibani W, Carone R, et al. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89(3):259-69. [Crossref] [PubMed]
- Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, et al. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89(1):1-8. [Crossref] [PubMed]
- Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106-13. [Crossref] [PubMed]
- Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology. 2008;72(4):803-7. [Crossref] [PubMed]
- Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology. 1999;53(1):71-6. Erratum in: Urology 1999;53(5):1072. [Crossref] [PubMed]
- Eyigor S, Karapolat H, Akkoc Y, Yesil H, Ekmekci O. Quality of life in patients with multiple sclerosis and urinary disorders: reliability and validity of Turkish-language version of Incontinence Quality of Life Scale. J Rehabil Res Dev. 2010;47(1):67-71. [Crossref] [PubMed]
- Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int. 2013;91(4):429-38. [Crossref] [PubMed]
- Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608-15. [Crossref] [PubMed] [PMC]
- Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int. 2009;103(11):1509-15. [Crossref] [PubMed]
- Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186-93. [Crossref] [PubMed]
- Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al; VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520-9. [Crossref] [PubMed]
- Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416-22. [Crossref] [PubMed]
- Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, et al; European Association of Urology. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62(6):1130-42. Erratum in: Eur Urol. 2013;64(1):e20. [Crossref] [PubMed]
- Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007;177(3):1011-4. [Crossref] [PubMed]
- Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27(4):311-4. [Crossref] [PubMed]
- Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98-S107. [PubMed]
- Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249-56. [Crossref] [PubMed]
- Onem K, Bayrak O, Demirtas A, Coskun B, Dincer M, Kocak I, et al; Turkish Urology Academy, Incontinence/Neurourology Study Group. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. Neurourol Urodyn. 2018;37(1):263-8. [Crossref] [PubMed]
- Sun Y, Luo D, Tang C, Yang L, Shen H. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(11):1779-88. [Crossref] [PubMed]
- Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36(1):142-7. [Crossref] [PubMed]
- López Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodríguez A, Moreno Bencardino C. Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis. Urology. 2017;100:53-8. [Crossref] [PubMed]
.: İşlem Listesi